Bone-Sparing by Ca Salts With & Without Extra Phosphorus

骨矿物质基本上是磷酸钙，这两种元素（Ca和P）都是骨获取所必需的。 在美国，典型的钙摄入量低于目前的建议，而典型的磷摄入量则高于目前的建议。因此 人们的注意力主要集中在通过补充和食品强化来增加钙的摄入。的 最常用于这些目的的盐是碳酸钙。但是，虽然平均磷摄入量往往是 充足或慷慨，但相当大比例的老年妇女摄入量低于RDA的70% 在任何给定的一天，磷，因此可以说是在磷缺乏的风险。当这些女人 给予合成代谢治疗和补充钙（作为碳酸盐）的组合，添加的钙可以 揭示并加重潜在的磷缺乏。这既是因为钙在肠道中结合磷酸盐， 减少其吸收（从而有效地降低磷摄入量），因为诱导骨 肥料本身会消耗磷，因此吸收的磷可能不足以 支持通过这种疗法可能增加骨矿物质量。 为了测试补充骨矿物质的两种成分在治疗骨质疏松症中的可能重要性和价值， 为了支持骨质疏松症的合成代谢治疗，我们提出了一项为期1年的随机试验，比较两组 特立帕肽治疗的绝经后骨质疏松妇女，钙补充剂， 磷（即，磷酸钙对碳酸钙）。主要的结果指标是骨的变化 矿物质含量超过一年的试验。次要结果是测量骨吸收 生物标志物，以评估磷酸盐相对于碳酸盐是否提高重塑。 含磷复合肥优越性的发现 成本中性变化的钙源和相应的 骨质疏松症的预防）。 矿物（S）_an_a_n，ci_，s_ 克赖顿大学医学中心 骨质疏松症研究中心 北纬601度。30街 Omaha，NE 关键人员。参见说明。根据需要使用续页 从PdnUNRInvestigator开始。按字母顺序列出所有其他关键人员 名称O_anization 提供所需 顺序，姓在前。 Robert P. Heaney，医学博士克雷顿大学 Robert R. Recker，医学博士克雷顿大学 克雷顿大学 钙补充剂将提供证据， 骨质疏松症协同治疗改善（以及可能 信息格式如下。 RoleonP_e_ 主要研究者 合作研究 合作研究 琼·M Lappe博士 披露许可声明。仅适用于SBIPJSTTR，参见说明。[]是[]否 PHS 398（修订版05/01）第2页表格第2页 主要研究者/项目负责人（最后，第一，中间）：Heaney，Robert P. 主要研究者/项目负责人的姓名必须在每一打印页和每一续页的顶部提供， 研究资助 目录 页码 首页...... 1 说明，

Bone mineral is basically calcium phosphate, and both elements (Ca and P) are required for bone acquisition. Typical Ca intakes in the U.S. are lower than current recommendations, and typical P intakes, higher. Thus attention has been focused mainly on increasing Ca intake, by supplementation and food fortification. The salt most commonly used for these purposes is calcium carbonate. But while the average P intake tends to be adequate or generous, nevertheless substantial proportions of older women ingest less than 70% of the RDA for phosphorus on any given day, and hence may be said to be at risk for P deficiency. When these women are given a combination of anabolic therapy and supplemental Ca (as the carbonate), the added Ca may uncover and aggravate the latent P deficiency. This is both because Ca binds phosphate in the gut and reduces its absorption (thereby effectively lowering the P intake still further) and because the induced bone anabolism will itself consume phosphorus, as a result of which absorbed phosphorus may not be sufficient to support the increase in bone mineral mass made possible by this therapy. To test the possible importance and value of supplementing both of the components of bone mineral in support of anabolic therapy of osteoporosis, we propose a 1-year randomized trial, comparing, in two groups of teriparatide-treated postmenopausal osteoporotic women, calcium supplements with and without extra phosphorus (i.e., Ca phosphate vs. Ca carbonate). The principal outcome measure will be change in bone mineral content over the one year of the trial. A secondary outcome is measurement of bone resorption biomarkers so as to assess whether the phosphate salt elevates remodeling relative to the carbonate salt. A finding of superiority of the phosphate-containing cost-neutral change in Ca sources and a corresponding osteoporosis prophylaxis as well). PERFORMANCESITE(S) _an_a_n, ci_,s_ Creighton University Medical Center Osteoporosis Research Center 601N. 30th Street Omaha, NE 68131 KEY PERSONNEL. See instructions. Use continuation pages as needed Start with Pdncipal Investigator. List all other key personnel in alphabetical Name O_anization to provide the required order, last name first. Robert P. Heaney, M.D. Creighton University Robert R. Recker, M.D. Creighton University Creighton University Ca supplement would provide evidence leading to a improvement in osteoporosis co-therapy (and possibly information in the format shown below. RoleonP_e_ Principal Investigator Co-investigator Co-investigator Joan M. Lappe, Ph.D. Disclosure Permission Statement. Applicable to SBIPJSTTR Only, See instructions. [] Yes [] No PHS 398 (Rev. 05/01 ) Page _2 Form Page 2 Principal Investigator/Program Director (Last, first, middle): Heaney, Robert P. The name of the principal investigator/program director must be provided at the top of each printed page and each continuation page, RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page .................................................................................................................................................. 1 Description,